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C O M M E N T A R Y
Reflections on The Global Influenza Surveillance and Response 
System (GISRS) at 65 Years:  An Expanding Framework for 
Influenza Detection, Prevention and Control
The history of influenza as a global health concern goes back centuries 
if not millennia. That history is mainly related to pandemics recognized 
long before the causative viruses had been identified.1 Their spread 
respected no borders, making them a global concern.2 The history of 
seasonal influenza is much shorter and less clear- cut, again starting 
well before the viruses were identified.3 The disease was recognized 
in large part because of the characteristic illnesses occurring over a 
relatively short period in the colder parts of the world. While the wide-
spread nature of influenza outbreaks was known, the recognition was 
largely limited to a number of countries, mainly in temperate regions.4 
Burden of disease was well recognized with estimates based on the 
methods that did not need to rely on virus identification of individual 
cases, but rather on the occurrence of the illnesses of certain char-
acteristics in periods with known virus circulation.5,6 That recognition 
led to the development of effective vaccines, starting in the 1940s.7 
Very quickly it became clear that changes in the influenza virus would 
make the vaccine ineffective unless it was updated regularly to reflect 
viruses in circulation and that circulation was global, not limited to a 
single country or region.
In much of the rest of the world at the time, the presence of the 
virus as a major cause of year- to- year illness was typically not recog-
nized. This was in contrast to pandemics, which because of the large 
number of cases of disease occurring over a limited time period were 
impossible to ignore. Only because of the programs seeking to iden-
tify the activity and characteristics of influenza viruses globally was 
there a beginning realization that the viruses were not only present in 
tropical countries but actually spread for much longer periods of time.8 
However, because of the lack of sharp seasonality, burden could not 
be estimated in the same way as in the temperate zones. The devel-
opment of the reverse- transcriptase polymerase chain reaction (PCR) 
technique made identification of actual infection easier, making it pos-
sible to define the periods of spread accurately, a necessity for deter-
mining impact when there was not sharp seasonality.9
Studies have begun to confirm the major impact of non- pandemic 
influenza not only in the countries where it was already partially rec-
ognized but also in much of the rest of the world, which until recently 
was all blank areas. Determination of burden has become one of the 
many activities at the World Health Organization (WHO) dedicated to 
influenza and its control. It is appropriate that this issue has come out 
in 2017, a year which marks the 65th anniversary of the antecedents 
of the Global Influenza Surveillance and Response System (GISRS). 
Without the system, whose predecessors started even before WHO 
was formally established, none of these activities would be possible, 
nor would there be an ability to respond to pandemics and to have 
vaccines formulated for use on an annual basis.
ESTABLISHMENT OF GLOBALLY 
COORDINATED INFLUENZA SURVEILLANCE
In 1947, the WHO Interim Committee of the United Nations agreed 
to begin a Global Influenza Programme (GIP) for the study and control 
of influenza. An immediate concern was a major outbreak of influenza 
in Europe and, recognizing influenza virus evolution, the need to iden-
tify appropriate viruses for a vaccine against the types of influenza 
which might be circulating. One year later, the Interim Committee 
recommended the establishment of the first World Influenza Centre 
at the National Institute for Medical Research in London along with 
Regional Centres and Observers. The 38 regional centers, later named 
National Influenza Centres (NICs), were called upon to participate in 
the effort. Extensive activity was undertaken to develop plans and 
coordinate information and virus sharing.
Five years after the establishment of GIP, WHO’s Executive Board 
decided that an influenza surveillance system was needed to inform 
the methods for disease prevention and control. The Global Influenza 
Surveillance Network (GISN) was born. The initial focus of GISN, later 
to be renamed the GISRS, was on standard diagnostic procedures, 
preparation, and distribution of diagnostic reagents, and the selec-
tion and evaluation of appropriate strains for vaccines. Research and 
training were also part of the overall effort, mainly focused on virus 
and strain diversity identification. At this point, understanding disease 
burden was largely restricted to describing seasonal outbreaks in tem-
perate countries experiencing sharp peaks of activity and enumerat-
ing influenza- related hospitalizations and deaths.5,6 In the rest of the 
world, the presence of the virus as a major cause of year- to- year illness 
was typically not recognized.
Global Influenza Surveillance and Response System gained mo-
mentum between the 1957 and 1968 pandemics. The growing net-
work of NICs and the Influenza Centres, later to be called Collaborating 
Centres for Reference and Research on Influenza (WHO CCs), focused 
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on understanding disease activity and characteristics of influenza vi-
ruses globally. These efforts confirmed the realization that the viruses 
were not only present in tropical countries but might circulate for 
much of the year.9
EXPANSION OF ACTIVITIES AND 
PREPARATION FOR A PANDEMIC
Although the main focus of GISRS activities in the subsequent years 
continued to be identification of influenza virus variants for making 
vaccine composition as close to the circulating strains as possible, 
there was gradual expansion to other aspects of influenza control. As 
examples, a system was adopted in 1980 unifying designation of the 
viruses by hemagglutinin and neuraminidase whatever the source.10 
Because of molecular studies, the human influenza viruses prevalent 
from 1918 to 1957, which had been previously termed ASw, A1, and 
A0, were all designated A(H1N1). This established the basic system of 
nomenclature used to this day. The antivirals, amantadine, and riman-
tadine were the subject of a consultation in 1983 as was evaluation of 
vaccine efficacy in the community in 1987. The former consultation 
was one of the first examples of expansion of activities into clinical 
concerns, a trend which has continued.
Surprisingly, even at that point, there was little global work at 
WHO in determining the burden of influenza on a global level. This 
was left to the individual countries and regions. An example of regional 
collaboration was the European Scientific Working Group on Influenza 
(ESWI). Their work was based on the realization that recommendations 
for vaccine use and support of research activities were dependent on 
recognition by governments both that influenza was a cause of signif-
icant morbidity and mortality and that interventions could mitigate its 
effect. Most studies demonstrating disease burden in various popu-
lation groups and potential reduction by vaccination were still being 
carried out mainly in the countries where seasonality of influenza was 
sharp.11 Some began to include economic components.12
At WHO, there were meetings in 1998 dedicated to influenza sur-
veillance, but the approach was changing, leading to more emphasis 
on regions with little prior knowledge of influenza activity and its im-
pact. By 2002, WHO’s Executive Board urged countries without na-
tional influenza vaccine policy to assess disease burden and economic 
impact of annual influenza epidemics. Concern about a possible severe 
influenza pandemic drove much of the activity for the rest of that de-
cade with recognition of multiple outbreaks of avian A(H5N1) viruses 
mainly in Asia, Africa, and even Europe which occasionally involved 
humans.13,14 Recommendations for the development and use of vac-
cines and antivirals were made as were efforts at preparing for rapid 
response.
As pandemic influenza is perceived as a threat in all countries, even 
in those which have had little prior interest in seasonal influenza, this 
allowed further expansion of efforts to detect influenza viruses to the 
countries which did not do so on a regular basis. Much of this expan-
sion was possible only because of what can only be described as a 
technologic breakthrough, the development, and the dissemination 
of polymerase chain reaction (PCR) technique. Influenza viruses could 
now easily be identified accurately with high sensitivity and specific-
ity. Global Influenza Surveillance and Response System supported and 
accelerated the process by the provision of reagents and training pro-
grams. As a result, the impact and seasonality of influenza in tropical 
and subtropical areas of the world were being better defined so that 
it became possible, to say when and how long influenza transmits in 
particular areas.
Many countries began to appreciate that influenza was present 
and active over a good part of the year. Global Influenza Surveillance 
and Response System facilitated the dissemination of information 
between countries, including information on disease burden. This en-
abled countries without disease burden information to begin to appre-
ciate the public health importance of influenza based on neighboring 
country or regional data. This also catalyzed countries to undertake 
their own studies, which in turn generated a greater demand for GISRS 
and GIP support.
MOVING INTO THE POST- PANDEMIC  
WORLD
The International Health Regulations had been put into effect shortly 
before the 2009 A(H1N1) pandemic establishing the critical role of 
WHO in the response.15 Global Influenza Surveillance and Response 
System and GIP played a central role during the pandemic, particu-
larly focusing on issues such as severe disease occurring in pregnant 
women. The burden of seasonal influenza in pregnant women and 
their offspring resulted in recommendations for the use of influenza 
vaccines in pregnancy. In 2012, updates to the WHO vaccine risk 
group recommendations further strengthened the need to demon-
strate burden. Without such demonstration, it will not be possible to 
convince much of the world that there is a need for seasonal vaccines, 
and without such use of seasonal vaccines, there will not be enough 
production capacity to supply the world with vaccines when the next 
pandemic occurs.
To facilitate countries to estimate their influenza disease burden 
and to build global estimates from such data, WHO issued a manual 
for estimating disease burden associated with seasonal influenza.16 
Estimation is premised on surveillance systems that can distinguish 
laboratory- confirmed disease from clinical syndromes. Many coun-
tries, and as evidenced in the studies represented in this issue, have 
relied on the work of their NICs to provide such information.
The next will be to demonstrate that vaccines can reduce severe 
disease. There is still, unfortunately, a belief in much of the world that 
influenza is a relatively mild, self- limited illness. Countries with other 
major health issues will not take influenza prevention seriously unless 
it is demonstrated that there is significant, preventable severe morbidity 
and mortality, particularly in children under 2 years of age. This can be 
demonstrated in many ways, including a vaccine probe study that allows 
both the demonstration of the burden of severe disease and the ability 
of the vaccine used to prevent it.17 Results can then be further extrapo-
lated to any new vaccines as development proceeds. With the increase 
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in surveillance and laboratory testing under the GISRS umbrella in places 
where such severe illnesses are still common, it is now possible to con-
duct such studies, which, by demonstrating that burden is preventable, 
will have a long- term effect on global control of influenza and its conse-
quences. Now, it is our opportunity to reflect on the collective success, 
collaboration, and international efforts of GISRS and to congratulate the 
various institutions involved for their contribution to the study and con-
trol of a disease of global health importance. Happy birthday GISRS!
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